Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — Tempus Labs — Technical Presentation (December 2021)
5 slides from Tempus Ai's technical presentation, December 2021
Slide 1: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma
Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity Andrew A. Davis1, Amir Behdad2, Kayla Viets Layng3, Firas Wehbe2, Lorenzo Gerratana4, Elizabeth Mauer3, Alex Barrett3, Ami N. Shah2, Pa
Slide 2: Background
Background • The genomic landscape of primary ILCs is well described, but less is known about metastatic ILC (mILC). • We used de-identified next-generation sequencing data to examine the co-mutational landscape of CDH1-mutant mILC. • Additionally, we investigated transcript-level expression variati
Slide 3: Somatic landscape of CDH1-mutant vs. CDH1-WT mILC cohorts
Somatic landscape of CDH1-mutant vs. CDH1-WT mILC cohorts CDH1 Wild−Type • PIK3CA mutations were enriched in CDH1 Wild−Type CDH1-mutant mILC compared to CDH1-WT mILC. CDH1 Mutated CDH1 Mutated • TBX3 and NCOR1 mutations were mildly enriched in CDH1-mutant mILC, RU RU1 1 1B 1B C C N NA A R1 R1 X1 X1
Slide 4: Comparing CDH1 gene expression between mILC and mixed histologies
Comparing CDH1 gene expression between mILC and mixed histologies a b c mILC Mixed mILC vs Mixed 5 Wilcoxon, p=0.82 5 Wilcoxon, p<0.001 5 Wilcoxon, p<0.001 Gene Expression Gene Expression Gene Expression 4 4 4 CDH1 Log10 CDH1 Log10 CDH1 Log10 3 3 3 2 2 2 1 1 1 0 0 0 CDH1 CDH1 CDH1 CDH1 mILC mixed WT
Slide 5: Conclusions
Conclusions • Our real-world dataset illustrates that the molecular landscape of CDH1-mutant mILC patients is distinct from CDH1-WT patients. • mILC differs from mixed histology at a transcriptional level, with lower CDH1 expression regardless of CDH1 mutational status. • CDH1 RNA levels in CDH1-mut